Enliven Therapeutics, Inc.
ELVN•NASDAQ•Healthcare•Biotechnology

About Enliven Therapeutics

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.

Company Information

SectorHealthcare
IndustryBiotechnology
CEORichard Fair
Founded2016
IPO DateMarch 12, 2020
Employees62
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNASDAQ (NASDAQ)
CurrencyUSD - USD
TypeStock

Corporate Identifiers

CIK0001672619
CUSIP29337E102
ISINUS29337E1029
EIN81-1523849
SIC2834

Leadership Team & Key Executives

Richard A. Fair
Chief Executive Officer, President and Director
Samuel S. Kintz M.B.A.
Co-Founder and Head of Pipeline
Dr. Joseph P. Lyssikatos Ph.D.
Co-Founder and Chief Scientific Officer
Dr. Helen Louise Collins M.D.
Chief Medical Officer
Anish Patel Pharm.D.
Co-Founder and Chief Operating Officer
Benjamin Hohl
Chief Financial Officer and Head of Corporate Development
Dr. Galya D. Blachman Esq., Ph.D.
Chief Legal Officer and Head of Business Development